HC Wainwright & Co. has downgraded Cidara Therapeutics Inc (CDTX) from a Buy rating to Neutral as of November 13, 2025. The company's current share price stands at $217.71.
This downgrade suggests increased caution regarding Cidara's outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that may affect its performance. Cidara Therapeutics, headquartered in San Diego, California, focuses on developing targeted immunotherapies aimed at improving patient care in serious diseases. The firm is advancing its Cloudbreak platform, which enables the creation of drug-Fc conjugates designed to engage the immune system while targeting specific disease markers.
Cidara's lead candidate, CD388, is a potent antiviral aimed at providing universal prevention and treatment of seasonal and pandemic influenza, having completed Phase I and Phase IIa clinical trials. The company also has an oncology candidate, CBO421, targeting CD73 for solid tumors. As of November 8, 2025, Cidara's market capitalisation is $2.5 billion, with a trailing twelve months EPS of -11.12. Upcoming earnings are scheduled for May 5, 2026, and August 4, 2026.
Analyst ratings and price targets are based on research and financial models, reflecting assumptions that may not always materialise. Therefore, investment decisions should consider various factors, including company fundamentals and industry trends, rather than relying solely on analyst opinions. Notably, analyst ratings can evolve over time as new information becomes available, and different analysts may hold varying views on the same company.